Information  X 
Enter a valid email address



Wednesday 19 May, 2021


Contract win for new neuroinflammatory disorder

RNS Number : 0509Z
19 May 2021


("IXICO" or the "Company")


Contract win for new neuroinflammatory disorder

Contract extends IXICO's CNS franchise to include a further new disease indication 


IXICO plc (AIM:IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been selected by a current biopharmaceutical client to provide neuroimaging services for a Phase III clinical trial . Following on from the recent contract win announcement made on 28th April for an acute ischemic stroke study, today's contract announcement is for a Neuroinflammatory disorder study, extending IXICO's CNS franchise to include a further new disease indication.  In addition to deepening the commercial relationship with this client, the additional contract highlights the Company's strategic momentum in diversifying across new neurological therapeutic areas. 


Neuroinflammatory disorders such as multiple sclerosis (MS) represent an important area of research within CNS, with an active and growing number of new clinical trials anticipated. The new Phase III trial will be conducted across 50 sites in North America and Europe and is worth in excess of £0.5m over 4 years.


Lammert Albers, Chief Commercial Officer of IXICO, commented:

" IXICO is delighted to be awarded the contract for this new study. By bringing together our Company's proven therapeutic expertise, advanced AI analytics and robust operational infrastructure, IXICO will enable this existing biopharmaceutical client to accelerate R&D decision making, de-risk clinical research and maximise the value of their CNS drug development pipelines. We are proud to support all sponsors in their tireless efforts to bring potential treatments to patients suffering from neurological disorders and the new award reflects the confidence customers place in IXICO as the trusted leading neuroimaging partner for their Phase III CNS studies."


For further information please contact:



+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer



Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales



Walbrook PR Ltd

+44 (0)20 7933 8780


Paul McManus / Lianne Cawthorne /

[email protected]

Alice Woodings



IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.


More information is available on   and follow us on Twitter @IXICOnews



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t